BFIM
UTHR icon

Beese Fulmer Investment Management’s United Therapeutics UTHR Stock Holding History

Beese Fulmer Investment Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$286K Sell
527
-67
-11% -$37.7K 0.02% 314
2026
Q1 		$352K Sell
594
-30
-5% -$14.9K 0.02% 271
2025
Q4 		$304K Buy
+624
New +$291K 0.02% 284

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Beese Fulmer Investment Management's UTHR Position: Q2 2026 in Review

Beese Fulmer Investment Management reduced its United Therapeutics (UTHR) stake by 11% in Q2 2026, selling an estimated $37.7K and leaving 527 shares worth $286K. The position accounts for 0.02% of the portfolio, ranked #314.

Beese Fulmer Investment Management first reported a position in UTHR in Q4 2025 and has held it in 3 quarters since. The position peaked at $352K in Q1 2026. 881 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Beese Fulmer Investment Management held 527 shares of United Therapeutics worth $286K as of Q2 2026.
  • Beese Fulmer Investment Management sold 67 United Therapeutics shares in Q2 2026, an estimated $37.7K.
  • United Therapeutics made up 0.02% of Beese Fulmer Investment Management's portfolio in Q2 2026, its #314 holding.
  • Beese Fulmer Investment Management first reported a position in United Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Beese Fulmer Investment Management's United Therapeutics position peaked at $352K in Q1 2026.
  • 881 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Beese Fulmer Investment Management's 13F filing for Q2 2026, filed 29 Jul 2026.